Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.24.1.1.u2
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 27, 2024
Dec. 31, 2023
Jul. 18, 2023
May 31, 2013
Reduction in Workforce, Percentage         70.00%  
Reduction in Workforce, Cost       $ 7,500    
Cash, Cash Equivalents, and Short-Term Investments $ 19,100          
Net Income (Loss) Attributable to Parent (4,892) $ (13,183)        
Retained Earnings (Accumulated Deficit) $ (319,856)     $ (314,964)    
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]            
Contracts Receivable, Claims and Uncertain Amounts     $ 20,000      
B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]            
Contracts Receivable, Claims and Uncertain Amounts     $ 55,000      
Pieris Pharmaceuticals GmbH [Member]            
Business Acquisition, Percentage of Voting Interests Acquired           100.00%